Biodimension develops biofabricated human tissues and organoids for drug and cosmetic safety testing, providing a non-animal alternative that yields more relevant human data. Their technology enhances the drug discovery process by offering customized, three-dimensional tissue models that accurately replicate human biological responses.
Funding
$12M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug and cosmetic safety testing relies heavily on animal models, which often fail to accurately predict human responses, leading to ineffective or unsafe products. Animal testing also raises ethical concerns and can be time-consuming and expensive.
Solution
Biodimension offers biofabricated human tissues and organoids as a non-animal alternative for drug and cosmetic safety testing, providing more relevant human data. These customized, three-dimensional tissue models accurately replicate human biological responses, enhancing the drug discovery process. Their technology allows for the screening of drugs and cosmetics for safety and toxicology using functional replicas of human tissues. By using biofabricated human tissues, Biodimension provides a more ethical and effective platform compared to traditional animal testing methods.
Target Audience
The primary customers are pharmaceutical and cosmetic companies seeking alternatives to animal testing for drug and product safety and efficacy assessments.
Features
- Biofabricated human tissue models that replicate natural tissues
- Patient-derived organoids in three-dimensional culture
- Customized tissue models tailored to specific research needs
- Cancer and diseased tissue models for targeted drug screening
- Non-animal testing models for ethical and effective safety assessments